The combined entity will benefit from a robust pipeline covering all major molecules coming off patent in the next five years
Aurobindo Pharma has inked a pact to acquire Portugal’s Generis Farmaceutica from Magnum Capital Partners for a consideration of 135 million euros (around Rs 969 crore).
The company has inked a binding agreement through its wholly-owned subsidiary Agile Pharma Netherlands to acquire Generis Farmaceutica for a total consideration of 135 million euros, Aurobindo Pharma said in a statement. Generis produces and sells pharma products in Portugal.
“The acquisition of Generis, by leveraging its strong portfolio and unrivalled brand recognition will allow us to establish ourselves as the top generics player in the Portuguese market,” Aurobindo SVP European Operations V Muralidharan said.
The combined entity will benefit from a robust pipeline covering all major molecules coming off patent in the next five years, he added.
“This acquisition coupled with our past acquisition activity underlines our commitment to focus on growth initiatives in European markets and will be a a key driver of growth for the future,” Muralidharan said.
Closing of the transaction, however, is conditional on obtaining necessary approvals from the Portuguese authorities.
The acquisition deal includes the Generiss manufacturing facility in Amadora, Portugal which has a capacity to produce 1.2 billion tablets/ capsules/ sachets annually.
Paulo Lilaia, CEO, Generis said the company would benefit immensely from Aurobindos vertical integration and strong product pipeline.
“Our large portfolio along with our unmatched commercial presence in Portugal will allow Aurobindo to consolidate its market position in Portugal,” he added.
With the latest acquisition, Aurobindo will now have a portfolio of 271 products in the European nation.
The Hyderabad-based firm has been steadily expanding its European footprint since 2006. In 2014 it has acquired Actaviss commercial operations in seven Western European countries.